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Objectives
●
●
●
●

Briefly review some context & consequences of the US obesity epidemic
Review available prescription anti-obesity medications
Discuss details specific to each of these medications
Review other medications affecting weight

After this lecture, I hope you will:
● Have a greater understanding of available anti-obesity medications
● Be more comfortable in patient discussions & management of obesity

What will not be covered
● Detailed discussion of causes & health consequences of obesity
● Detailed discussion of lifestyle changes, bariatric surgery, and other nonpharmacotherapy interventions
● Thorough analysis of evidence
● Insurance coverage
● Investigational drugs
● OTC supplements
● Medications used outside the US

Definitions
Morbid Obesity:
● BMI > 40
● BMI > 35 + at least
one serious obesity
related condition
● >100 pounds over
ideal body weight
Severe Obesity:
● BMI >120% of
95th percentile

US Obesity statistics, 2017-18
●
●
●
●

42% of Adults, 9% BMI >40 (31%, 5% BMI > 40 in 1999-2000)
19% of Children & Adolescents, 6% severe (14%, 3.6% severe in 1999-2000)
$147 Billion in 2008 ($79B in 1998)
Impact of Income
○
○

Men: Higher rates in middle income
Women: Lower rates of obesity in high income

● Impact of Education:
○
○

Men: Lower rates in college graduates for white men
Women: Lower rates in college graduates for white, black & hispanic women

Obesity Health Outcomes

Mortality, on average,
~30% higher
for every 5 kg/m2 BMI > 25

Exponential increase in
risk of CV death as adult
with rising BMI
in late adolescence

Increased risk of
T2DM, HTN, CAD
& Cholelithiasis
with higher BMI or
weight gain

Increased risk:

Case 1
ES is a 61yo female with pmh Anxiety, Depression, Hypothyroidism, Obesity,
HLD, h/o Covid presenting to discuss her weight. Her BMI today is 34.6. She tells
you that she has struggled with her weight her entire adult life. In 2005 she
decided to proceed with bariatric surgery, but that the surgery was ultimately
aborted day of due to an adverse reaction to the anesthesia with acute CHF and
pulmonary edema requiring ICU stay from which she is now fully recovered. She
recently underwent a repeat bariatric eval at Jeff but decided to pause it due to her
history. She tried orlistat previously, but was unable to tolerate it. She has been
trying lifestyle changes but is interested in medication to help with the weight loss.
Recent lab work shows HLD & Hypothyroidism well controlled and multiple recent
BGs < 100. Her insurance is medicare / medicaid.

Case 2
DB is a 37yo male with pmh DM, obesity, HTN, depression (in remission, not on
meds), and h/o covid who presents as follow up after starting insulin and to
discuss his weight. His BMI is 47 at today’s visit. You recently started him on
insulin for his uncontrolled DM (A1c 12), in addition to his trulicity and metformin.
He had been working on losing weight and is concerned about weight gain
associated with insulin; he was on insulin once prior a remembers being told it
could lead to weight gain. His insurance is Keystone Managed Care.

Case 3
JM is a 40 yo female with pmh prolactinoma (not on meds, asx, normal prolactin),
HLD, overweight coming as follow up after an annual physical to discuss her
weight. Her BMI today is 29. Her labs from last month showed A1c 5.2, normal
renal fx, Tchol 253 with LDL 177; she has recent TSH 1.97. She is concerned
about weight gain over the past few years. Her insurance is Keystone Managed
Care.

Obesity Management Options
1. Lifestyle Changes
2. Pharmacotherapy
3. Surgery

Lifestyle Changes
● Comprehensive:
○ ~3% net wt loss (vs control)
● Diet:
○ 800-1200 kcal/day
● Exercise:
○ Prevents weight regain
○ “Dose effect”

Bariatric Surgery
● Indications
○ BMI > 40
○ BMI > 35 + comorbidity
○ BMI > 30 + DM (for diabetes control)
● Outcomes: (at 1 and 5 years)
○ RYGB: -31%, -25%
○ Gastric Sleeve: -25%, -19%
○ Gastric Band: -14%, -12%
● 30 day rates of major adverse events: 2.6-5%

Weight Loss Pharmacotherapy

History of weight loss medications
2,4 Dinitrophenol
(2,4 DNP)

Late
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Thyroid
extract
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approved

Rainbow pills
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Rainbow pills;
Desoxyephedrine
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Orlistat approved
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History of weight loss medications
Orlistat approved
for OTC use
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withdrawn
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2014
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&
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Lorcaserin
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Semaglutide (Wegovy)
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Indications
● BMI ≥ 30
● BMI ≥ 27, with comorbid obesity-related risk factors or diseases

General Recommendations
●
●
●
●

Use in conjunction with lifestyle changes
Offer for chronic use
Goal > 5% weight loss
Assess monthly for first 3m, then q3m

General Contraindications
● Avoid if:
○ Pregnancy or Breastfeeding
○ Severe hepatic impairment
● Use with caution if:
○ > 65y
○ CKD
○ Hepatic impairment
○ Psychological disorders

Currently FDA Approved Medications (chronic use, >6mo)
● Orlistat (Xenical)
● Liraglutide (Saxenda)
● Semaglutide (Wegovy)
● Phentermine + ER topiramate (Qsymia)
● Naltrexone/Bupropion ER (Contrave)

Orlistat (Xenical, Alli)
●
●
●
●
●
●

● $700/mo (goodRx)
● $50 OTC (Alli, 60mg)
(at Walmart, goodRx)

Class: Intestinal Lipase Inhibitor
Dose: 120 mg PO TID
Efficacy: 17lbs weight loss (vs 10lbs) in 1st year; maintained 2-3y
Metabolic Effects: ↓BP, Lipids
AEs: GI intolerance, ?liver injury, Fat-soluble vitamins, Ca-Oxalate stones
Contraindications / Considerations:
○
○
○

Chronic malabsorption, cholestasis,
Ca-Ox stones, pancreatitis
Interferes w/Cyclosporin, Levothyroxine absorption
May need to adjust (decrease) warfarin dose

● Other Notes:
○
○

Low fat diet OK
May be beneficial in NAFLD

Liraglutide (Saxenda, Victoza)

● $1400/mo (goodRx)
● As little as $25, max
$200 off, up to 12 uses
(commercial insr only)

● Class: GLP-1 receptor agonist
● Dose: 3mg SC qd
● Efficacy: 11-16lbs (vs 6lbs placebo, 9lbs orlistat) @20wks (dose dependent)
○

50-75% pts w/ >5% wt loss (vs 30%, 44%)

● Metabolic Effects: ↓Major cardiac events (in DM & pre-existed CVD); mild ↓BP,
↓preDM / delayed progression to DM
● AEs: GI (n/v/d), pancreatitis, gallbladder disorders
● Contraindications / Considerations:
○
○

Black box: Thyroid C-cell tumors (MEN 2)
H/o pancreatitis

● Other Notes:
○

Prime pen before 1st dose

Semaglutide (Wegovy, Ozempic)

● $1400/mo (goodRx)
● As little as $25, max
$200 off, up to 6 uses
(commercial insr only)

● Class: GLP-1 receptor agonist
● Dose: 2.4mg SC qw
● Efficacy: 34lbs (vs 6lbs) @68wks
○
○

>5% wt loss: 87% (vs 32%)
>10% wt loss: 69% (vs 12%)

○
○

>15% wt loss: 51% (vs 5%)
>20% wt loss: 20% (vs 1.7%)

● Other Health Effects: ↓Major cardiac events (in DM & pre-existed CVD or CKD),
↓BP (6mmHg)
● AEs: Same
● Contraindications / Considerations: Same
● Other Notes:
○
○
○

More intensive lifestyle changes
not associated w/greater weight loss
Weight regain with d/c @20wks
Trials with great retention rates - 90%

Bupropion-Naltrexone ER (Contrave)
●
●
●
●
●
●

● Limited insr coverage
● $300/mo (goodRx)
● $100, max $188 off
(commercial insr only)

Class: DNRI, mu-Opioid-receptor antagonist
Dose: 8 mg/90 mg (1 tab) qd, may be increased to 2 tabs BID (+1 tab / week)
Efficacy: 5-6% wt loss (vs 1%)
Other Health Effects: neutral to negative effect on BP, HR (increases)
AEs: GI (mostly nausea, constipation), HA
Contraindications / Considerations:
○
○
○

Possible increased in CV events (trial stopped early)
Max 1 tab qd for mod-severe renal or hepatic impairment
Avoid with: Seizures, Eating disorders, poorly controlled HTN, Opiates / MAT

● Other Notes:
○
○

Suggested for smokers w/obesity who want to quit smoking
Unclear if naltrexone has added effect

Phentermine + ER topiramate (Qsymia)

● Limited insr coverage
● $200/mo (goodRx)
● $70, max $65 off
(commercial insr only;
no HSA account)

● Class: Sympathomimetic + GABA / AMPA glutamate
● Dose: 3.75mg/23mg PO qd x2wk, then 7.5mg/46mg (max 15mg/92mg)
● Efficacy: 18-22lbs, (vs 3lbs) @1yr, dose dependent; stable @2yr
○
○

>5% wt loss: 62-70% (vs 21%)
>10% wt loss: 37-48% (vs 7%)

● Other Health Effects: ↓DM (~50% vs placebo)
● AEs: paresthesias, dizziness, insomnia, altered taste, constipation,
tachycardia, dry mouth, memory / cognitive changes
● Contraindications / Considerations:
○

Avoid in CVD (HTN, CAD)

● Other Notes:
○
○
○

Considered 3rd line after GLP1 RA & Orlistat
Abrupt withdrawal may cause seizures
Dose adjustment in CKD or liver impairment

Other drugs: Sympathomimetics
●
●
●
●
●
●

Phentermine
● $10-15 (goodRx)

Phentermine (Adipex-P), Diethylpropion, Benzphetamine, & Phendimetrazine
Dose: Phentermine: 15-37.5 mg/day, 1 to 2 divided doses
Efficacy: net 16lbs wt loss @36wks (vs placebo, 1959 study)
Other Health Effects:
AEs: ↑BP, ↑HR, insomnia, constipation, dry mouth, nervousness
Contraindications / Considerations:
○

CAD, uncontrolled HTN, hyperthyroidism, h/o drug abuse

● Other Notes:
○
○

Only approved for short term use (<12wk)
■ Used by some experts long-term in select patients
Generic Phetermine most commonly prescribed wt loss drug

Other drugs: Recently Recalled
Lorcaserin (Belviq): 2012-2020
● Withdrawn from market 2020
● Linked to increased cancer
● No recommended cancer
screening / monitoring

Sibutramine (Meridia): 1997-2010
● Withdrawn from market 2010
● Linked to increased CV events
(in high risk patients)

Other medications with associated Weight Loss
● Metformin: 10-15% higher rate of long-term wt loss [pts w/elevated glucose]
● Bupropion: minimal wt loss (vs placebo) [pts w/binge-eating]
● Fluoxetine: minimal wt loss (vs placebo) for high dose (60mg) only
● Zonisamide: -10 to 16lbs, 3-4x rates of >10% wt loss (vs placebo)
● Exenatide: -8lbs, 2x rate >5% wt loss (vs placebo)
● Pramlintide: minimal wt loss (vs placebo)
● Canagliflozin: minimal wt loss; ~2x rate >5% wt loss (vs placebo) for high dose

Weight Loss Supplements of note
●
●
●
●

Litramine: soluble fiber
Green Tea: hepatotoxicity
Hydroxycut: too many products to evaluate
Ephedra (ma huang): products not available in US
○

"Ephedra-free" -- ephedrine-like substances, “bitter orange, country mallow, or heartleaf”

Medications with associated Weight gain
Class

Weight gain

Alternatives meds (neutral / wt loss)

Antipsychotic

thioridazine, olanzapine, risperidone, clozapine, ziprasidone, haloperidol, aripiprazole
quetiapine

Antidepressant

MAO-I, TCA, SSRIs (paroxetine, citalopram,
escitalopram), Mirtazapine, Trazadone

Bupropion, SNRIs, SSRI (Fluoxetine,
Sertraline)

Anti-diabetic

Insulin, Sulfonylureas, Thiazolidinediones,
Meglitinides

GLP1-RA, Metformin, SGLT2-RA,
DDP4-I

Steroids

Glucocorticoids, Depo-provera

OCPs

Anticonvulsants,
Mood stabilizers,
other neuro meds

Divalproex, Carbamazepine, valproate
Lithium
Gabapentin

Topiramate, Zonisamide, Lamotrigine

Antihistamines

All

Beta-blockers

Especially Propranolol

Case 1 - Recap
ES is a 61yo female with pmh Anxiety, Depression, Hypothyroidism, Obesity,
HLD, h/o Covid presenting to discuss her weight. Her BMI today is 34.6. She tells
you that she has struggled with her weight her entire adult life. In 2005 she
decided to proceed with bariatric surgery, but that the surgery was ultimately
aborted day of due to an adverse reaction to the anesthesia with acute CHF and
pulmonary edema requiring ICU stay from which she is now fully recovered. She
recently underwent a repeat bariatric eval at Jeff but decided to pause it due to her
history. She tried orlistat previously, but was unable to tolerate it. She has been
trying lifestyle changes but is interested in medication to help with the weight loss.
Recent lab work shows HLD & Hypothyroidism well controlled and multiple recent
BGs < 100. Her insurance is medicare / medicaid.

Case 1
What do you recommend?

Case 2
DB is a 37yo male with pmh DM, obesity, HTN, depression (in remission, not on
meds), and h/o covid who presents as follow up after starting insulin and to
discuss his weight. His BMI is 47 at today’s visit. You recently started him on
insulin for his uncontrolled DM (A1c 12), in addition to his trulicity and metformin.
He had been working on losing weight and is concerned about weight gain
associated with insulin; he was on insulin once prior a remembers being told it
could lead to weight gain. His insurance is Keystone Managed Care.

Case 2
What do you recommend?

Case 3
JM is a 40 yo female with pmh prolactinoma (not on meds, asx, normal prolactin),
HLD, overweight coming as follow up after an annual physical to discuss her
weight. Her BMI today is 29. Her labs from last month showed A1c 5.2, normal
renal fx, Tchol 253 with LDL 177; she has recent TSH 1.97. She is concerned
about weight gain over the past few years. Her insurance is Keystone Managed
Care.

Case 3
What do you recommend?

Key Points
●
●
●
●
●
●
●

Obesity is a growing problem
Not so distant history of dubious weight loss medications
Consider starting medication simultaneous with lifestyle changes
Recommended for long-term use (>6mo)
Cost is a significant issue
Recommend low-fat diet with Orlistat
Wegovy (Semaglutide) approaches bariatric surgery outcomes!

Questions?

